FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1480918649> ?p ?o ?g. }

• W1480918649 endingPage "1150" @default.
• W1480918649 startingPage "1149" @default.
• W1480918649 abstract "Proc Amer Assoc Cancer Res, Volume 47, 20064892 EGCG is the main polyphenol extracted from green tea. It has shown anti-tumor or chemopreventive activity in several tumors including SCCHN by regulating EGFR-mediated pathways. We hypothesize that a combination of EGCG and an EGFR-TKI (erlotinib) may synergistically inhibit tumor growth of SCCHN. Five head and neck cancer cell lines (Tu212, Tu177, 886LN, SQCCY1, and 38) were used for this study. Cell growth inhibition assay showed that treatment with two drugs as single agent for 72 hrs inhibited growth of all five SCCHN cell lines in a dose dependent manner. Combination index (CI) analysis demonstrated that the combined treatment of EGCG with erlotinib for 72 hrs achieved synergistic effects (CI < 1) of cell growth inhibition on four of five cell lines except an additive effect on 886LN. We selected two representative cell lines, Tu212 and Tu177 to further investigate the underlying mechanisms using fixed concentration of EGCG (30 μM) and erlotinib (0.5 μM). Cell cycle analysis showed a significant G1 arrest after the combined treatment of the two cell lines for 24 and 48 hrs compared to either the single treatment or the control group. Annexin-V binding assay demonstrated more apoptotic cells in the combined treatment group compared to either the single agents or the control group. Immunoblotting analyses showed that the combined treatment significantly reduced the phosphorylation of EGFR and AKT. The combined treatment also induced activation of caspase-8, caspase-9, caspase-3 and PARP compared to either the single agents or the control group. In our in vivo study, twenty five nude mice were randomly divided into four groups. Each group was orally gavaged with the vehicle control (1% tween 80), EGCG (125 mg/kg), erlotinib (50 mg/kg) or a combination of EGCG and erlotinib at the same doses for 7 days followed by a subcutaneous injection with 2 × 106 of Tu212 cells. The animals were continuously administered the agents 5 days a week. The tumor size in each mouse was measured three times per week until all mice were sacrificed once the tumor size of any mouse reached 2cm in diameter. Our results showed that the combination treatment (443 ±120 mm3) significantly inhibited the tumor growth compared to the control (2743 ± 910 mm3), EGCG alone (1198 ± 406 mm3) or erlotinib alone (1176 ± 392 mm3), (p = 0.005). The mean time (days) to reach a tumor volume of 400 mm3 was significantly delayed in the combined treatment (34.2 ± 2.4) as compared with the control (21.2 ± 2.8), EGCG (23.7 ± 2.1), or erlotinib (23.7 ± 1.3), (p = 0.005). Taken together, both our in vitro and in vivo results demonstrate significant anti-tumor activity for the combined treatment with EGCG and erlotinib. This combination provides a novel and promising chemopreventive regimen for SCCHN. (Supported by NCI UO1 101244)" @default.
• W1480918649 created "2016-06-24" @default.
• W1480918649 creator A5005934893 @default.
• W1480918649 creator A5010399375 @default.
• W1480918649 creator A5017825677 @default.
• W1480918649 creator A5018471110 @default.
• W1480918649 creator A5030308961 @default.
• W1480918649 creator A5039814984 @default.
• W1480918649 creator A5068111011 @default.
• W1480918649 date "2006-04-15" @default.
• W1480918649 modified "2023-09-26" @default.
• W1480918649 title "Synergistic tumor growth inhibition by combined treatment with green tea epigallocatechin-3-gallate (EGCG) and an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), erlotinib in squamous cell carcinoma of the head and neck (SCCHN)" @default.
• W1480918649 hasPublicationYear "2006" @default.
• W1480918649 type Work @default.
• W1480918649 sameAs 1480918649 @default.
• W1480918649 citedByCount "1" @default.
• W1480918649 countsByYear W14809186492012 @default.
• W1480918649 crossrefType "journal-article" @default.
• W1480918649 hasAuthorship W1480918649A5005934893 @default.
• W1480918649 hasAuthorship W1480918649A5010399375 @default.
• W1480918649 hasAuthorship W1480918649A5017825677 @default.
• W1480918649 hasAuthorship W1480918649A5018471110 @default.
• W1480918649 hasAuthorship W1480918649A5030308961 @default.
• W1480918649 hasAuthorship W1480918649A5039814984 @default.
• W1480918649 hasAuthorship W1480918649A5068111011 @default.
• W1480918649 hasConcept C121608353 @default.
• W1480918649 hasConcept C126322002 @default.
• W1480918649 hasConcept C185592680 @default.
• W1480918649 hasConcept C190283241 @default.
• W1480918649 hasConcept C2777506169 @default.
• W1480918649 hasConcept C2778087573 @default.
• W1480918649 hasConcept C2778820342 @default.
• W1480918649 hasConcept C2779438470 @default.
• W1480918649 hasConcept C2779707156 @default.
• W1480918649 hasConcept C2909325608 @default.
• W1480918649 hasConcept C502942594 @default.
• W1480918649 hasConcept C55493867 @default.
• W1480918649 hasConcept C62112901 @default.
• W1480918649 hasConcept C71924100 @default.
• W1480918649 hasConcept C88634738 @default.
• W1480918649 hasConcept C98274493 @default.
• W1480918649 hasConceptScore W1480918649C121608353 @default.
• W1480918649 hasConceptScore W1480918649C126322002 @default.
• W1480918649 hasConceptScore W1480918649C185592680 @default.
• W1480918649 hasConceptScore W1480918649C190283241 @default.
• W1480918649 hasConceptScore W1480918649C2777506169 @default.
• W1480918649 hasConceptScore W1480918649C2778087573 @default.
• W1480918649 hasConceptScore W1480918649C2778820342 @default.
• W1480918649 hasConceptScore W1480918649C2779438470 @default.
• W1480918649 hasConceptScore W1480918649C2779707156 @default.
• W1480918649 hasConceptScore W1480918649C2909325608 @default.
• W1480918649 hasConceptScore W1480918649C502942594 @default.
• W1480918649 hasConceptScore W1480918649C55493867 @default.
• W1480918649 hasConceptScore W1480918649C62112901 @default.
• W1480918649 hasConceptScore W1480918649C71924100 @default.
• W1480918649 hasConceptScore W1480918649C88634738 @default.
• W1480918649 hasConceptScore W1480918649C98274493 @default.
• W1480918649 hasLocation W14809186491 @default.
• W1480918649 hasOpenAccess W1480918649 @default.
• W1480918649 hasPrimaryLocation W14809186491 @default.
• W1480918649 hasRelatedWork W1532286907 @default.
• W1480918649 hasRelatedWork W2028288529 @default.
• W1480918649 hasRelatedWork W2043396761 @default.
• W1480918649 hasRelatedWork W2088377303 @default.
• W1480918649 hasRelatedWork W2112407296 @default.
• W1480918649 hasRelatedWork W2324594876 @default.
• W1480918649 hasRelatedWork W2381300068 @default.
• W1480918649 hasRelatedWork W2382507743 @default.
• W1480918649 hasRelatedWork W2385601713 @default.
• W1480918649 hasRelatedWork W2386310850 @default.
• W1480918649 hasRelatedWork W2391039679 @default.
• W1480918649 hasRelatedWork W2585501848 @default.
• W1480918649 hasRelatedWork W2888748511 @default.
• W1480918649 hasRelatedWork W2939788355 @default.
• W1480918649 hasRelatedWork W3032792876 @default.
• W1480918649 hasRelatedWork W3150812937 @default.
• W1480918649 hasRelatedWork W3158730794 @default.
• W1480918649 hasRelatedWork W3184676253 @default.
• W1480918649 hasRelatedWork W2160212402 @default.
• W1480918649 hasRelatedWork W2354239616 @default.
• W1480918649 hasVolume "66" @default.
• W1480918649 isParatext "false" @default.
• W1480918649 isRetracted "false" @default.
• W1480918649 magId "1480918649" @default.
• W1480918649 workType "article" @default.